The level of haemoglobin in anaemic cancer patients correlates positively with quality of life

M. Lind, C. C. Vernon, Deborah Cruickshank, +7

British Journal of Cancer

Phase II Studies of RMP-7 and Carboplatin in the Treatment of Recurrent High Grade Glioma

A. Gregor, M. Lind, Hunter Newman, +4

Journal of Neuro-Oncology

Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial

Renaud Léonard, M. Lind, C.J. Twelves, +12

JNCI Journal of the National Cancer Institute

O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC

Thomas J. Lynch, R. Raju, M. Lind, +6

Lung Cancer

Advanced NsclcMedicineClinical TrialsPathologyPharmacotherapy +8

Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer.

Andrew Weaver, Jennifer C. Chang, E. Wrigley, +12

Journal of Clinical Oncology

Spina bifida and sexuality

Marie‐Louise von Linstow, I Biering-SÃ ̧rensen, A Liebach, +3

Journal of Rehabilitation Medicine

Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.

Imran Rafi, G. A. Taylor, J A Calvete, +7

PubMed

PharmacotherapyClinical PharmacokineticPharmacodynamic StudiesPharmacodynamic ModelingTranslational Pharmacology +14

A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles

Denis J. Murphy, D. Crowther, J. Renninson, +7

Annals of Oncology

MedicineMetronomic TherapyGynecologyOvarian CarcinomaMetronomic Chemotherapy +7

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

Gordon Rustin, Nicholas Reed, Gordon C. Jayson, +12

Annals of Oncology

Phase Ii TrialMedicinePharmacologyClinical TrialsGynecology +8

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels

Saad Ghazal‐Aswad, M.J. Tilby, M. Lind, +4

Annals of Oncology

Drug-plasma AucDose EscalationEpithelial Ovarian CancerMedicinePharmacology +6